Clioquinol
As of the edition of 20 October 2026, Clioquinol is a small molecule: marketed, first approved in 1957 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Nystaform
- First approved
- 31 December 1957 (CA)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- SMARTPRACTICE DENMARK (DANEMARK); 4 holders in all
- Withdrawn from market
- 1 January 1973 (in some regions)
- Registered trials
- 3, 1 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Heart and blood vessels; Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Knight Therapeutics | Applicant | 1957 to now |